Yale is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by our Clinical Center Director and Principal Investigator, Kevan Herold, MD, the TrialNet team at Yale is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
My background and research are in translational immunology. I am interested in understanding the basis for autoimmune diseases and developing new therapies based on our understanding of disease mechanisms. My focus has largely been in the field of autoimmune Type 1 diabetes. The work encompasses basic laboratory work understanding the regulation of autoreactive T cells to clinical trials that involve novel therapeutics. As part of these studies I have also been very interested in analysis of beta cell function in Type 1 diabetes.